ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio is viewed positively because ANKTIVA’s FDA expansion into high-risk BCG-unresponsive papillary-only NMIBC materially broadens the addressable U.S. market, which management says represents upwards of 60% of high-risk BCG-UR patients, while the original CIS +/- papillary data already showed a 62% complete response and 58% of responders maintaining response for at least 12 months. The company’s commercial case is further strengthened by its exclusive U.S. rights to the Tokyo-172 BCG strain, which could help reduce supply bottlenecks and support broader adoption in bladder cancer, where ANKTIVA already has a differentiated, durability-focused profile versus competitors. Beyond bladder cancer, ASCO 2026 data in NSCLC and supportive comparative analyses suggest ANKTIVA is a broader immune-restoration platform with meaningful long-term optionality, reinforcing a bullish fundamental outlook.

ImmunityBio is facing a fundamental regulatory overhang because the FDA continues to question whether single-arm papillary-only data can separate ANKTIVA’s effect from the roughly 50% curative floor associated with TURBT, and that skepticism persists in both the 2018 and updated 2024 guidance. The agency’s refusal to accept non-randomized data in the papillary population, echoed in the sBLA acceptance communication for QUILT 3.032 Cohort B, raises execution risk and suggests the path to broader approval may require a costly randomized study. That dependence on additional trials, rather than clear-cut clinical evidence, weakens the investment case and keeps commercialization uncertainty elevated despite the company’s Cancer BioShield platform and lead asset ANKTIVA.